Skip to main content

Table 5 Genotypic and immuno-trophic characteristics at the time of genotyping associated with virological suppression after 48 weeks of initiation of the rescue scheme

From: Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure

Viral Load (VL)
Characteristics Detectable
n (%)
Undetectable
n (%)
PR PR 95% IC P-value
Age (years)      0, 662a
 18–30 6 (11, 5) 13 (12, 2) 0, 92 0, 45 – 1, 86  
 31–50 40 (76, 9) 76 (71, 0) 1, 00  
  > 50 6 (11, 5) 18 (16, 8) 0, 73 0, 35 – 1, 52  
Gender      0, 385a
 Male 36 (69, 2) 81 (75, 7) 0, 81 0, 50 – 1, 29  
 Female 16 (30, 8) 26 (24, 3) 1, 00  
VL on genotypic result (copies/ml)      0, 752a
  ≤ 10.000 18 (35, 3) 36 (34, 3) 1, 00  
  > 10.000 a 100.000 20 (39, 2) 47 (44, 7) 0, 90 0, 53 – 1, 52  
  > 100.000 13 (25, 5) 22 (21, 0) 1, 11 0, 63 – 1, 98  
CD4 on genotypic result (cells/mm3)      0, 796a
  < 200 20 (38, 5) 45 (42, 9) 0, 95 0, 54 – 1, 66  
 200–350 18 (34, 6) 31 (29, 5) 1, 13 0, 64 – 1, 99  
  > 350 14 (26, 9) 29 (27, 6) 1, 00  
Number of NRTI resistance mutations      0, 179a
 zero 6 (11, 6) 10 (9, 3) 1, 00  
  < 3 32 (61, 5) 52 (48, 6) 1, 02 0, 51 – 2, 02  
  ≥ 3 14 (26, 9) 45 (42, 1) 0, 63 0, 29 – 1, 38  
N° of thymidine analogue mutation      0, 058a
 zero 35 (67, 3) 54 (50, 4) 1, 00  
  < 3 14 (26, 9) 34 (31, 8) 0, 74 0, 45 – 1, 24  
  ≥ 3 3 (5, 8) 19 (17, 8) 0, 35 0, 12 – 1, 02  
Number of NNRTI resistance mutations      0, 113a
  ≤ 2 32 (61, 5) 79 (73, 8) 1, 00  
  > 2 20 (38, 5) 28 (26, 2) 1, 45 0,93 – 2,25  
Number of PI resistance mutations      1, 000b
  ≤ 2 4 (80, 0) 14 (77, 8) 1, 00  
  > 2 1 (20, 0) 4 (22, 2) 0, 90 0, 13 – 6, 35  
M184 V/I mutation      0, 693a
 Yes 44 (84, 6) 93 (86, 9) 1, 00  
 no 8 (15, 4) 14 (13, 1) 1, 13 0, 62 – 2, 07  
  1. aChi-square test bFisher’s exact test, PR prevalence ratio, CI Confidence interval, CD4: CD4 T cells, CV viral load, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, NRTI nucleoside reverse transcriptase inhibitor